Dieter Juengst

Dept of Medicine II, University of Munich, Germany

Professor Juengst is Associate Professor of Medicine at the Department of Medicine II, Klinikum Grosshadern, University of Munich in Germany. He is a consultant in internal medicine, focusing on gastrointestinal and hepatological diseases.

His research mainly focuses on the pathogenesis of cholesterol gallstones; the effect of ursodeoxycholic acid on lipid peroxidation and mucin secretagogue activity of gallbladder bile in patients with gallstones; and local, adjuvant and systemic treatment of hepatocellular carcinoma.

Professor Juengst is a member of the Bavarian Association of Gastroenterology and Internal Medicine, the German Association of Gastroenterology, Oncology and Hepatology, the American Gastroenterological Association. He is also on the Editorial Board of Case Reports in Gastroenterology

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Gastroenterology & Hepatology > Biliary Tract (since 17 November 2006)

Links

http://www.med.uni-muenchen.de/index.html

All recent recommendations

• 6.0
  Sorafenib in advanced hepatocellular carcinoma.
  Recommended by Dieter Juengst
  
• 4.8
  Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial.
  Recommended by Michael Trauner with Martin Wagner and Gernot Zollner, Dieter Juengst
  
• 3.0
  Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients.
  Recommended by Dieter Juengst
  
• 3.0
  Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis.
  Recommended by Dieter Juengst
  
• 3.0
  A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C.
  Recommended by Dieter Juengst
  
• 6.0
  Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
  Recommended by Dieter Juengst
  
• 3.2
  Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones.
  Recommended by Cynthia Ko, Dieter Juengst
  
• 3.0
  Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy.
  Recommended by Dieter Juengst
  
• 3.0
  A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease.
  Recommended by Dieter Juengst with Professor Peter Lohse
  
• 3.0
  Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.
  Recommended by Dieter Juengst
  
• 3.0
  Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage.
  Recommended by Dieter Juengst
  
• 3.0
  Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis.
  Recommended by Dieter Juengst
  
• 6.0
  Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial.
  Recommended by Dieter Juengst
  
• 6.0
  Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid.
  Recommended by Dieter Juengst
  
• 3.0
  Cholecystectomy or gallbladder in situ after endoscopic sphincterotomy and bile duct stone removal in Chinese patients.
  Recommended by Dieter Juengst